China Pemetrexed Market Forecast to 2018
The report “Investigation Report on China Pemetrexed Market, 2009-2018″ by China Research and Intelligence is now available at chinamarketresearchreports.com. Contact sales@chinamarketresearchreports.com with Research Report on Investigation Report on China Pemetrexed Market, 2009-2018 in subject line and your contact details to purchase this report or get your questions answered.
The collection of ‘Life Sciences’ market research reports has a new addition of “Investigation Report on China Pemetrexed Market, 2009-2018”On chinamarketresearchreports.com . Pemetrexed, originally developed by Eli Lilly and Company, is a multitargeted antimetabolite antitumor drug. This product is with huge growth potential in the market.
Approved by FDA in February 2004, pemetrexed is to treat unresectable malignant pleural mesothelioma with cisplatin. It is the first drug approved by FDA to treat the disease. In August 2004 pemetrexed was approved as a secondline drug for local or metastatic nonsmall cell lung cancer.
So far pemetrexed (brand name "Alimta") has been approved to more than 60 countries worldwide. The product has been a best seller of Eli Lilly and Company since it was launched, and its sales value keeps increasing year after year. The CAGR of sales value of pemetrexed was 50.6% from 2004 to 2011. The sales value was only USD 140 million in 2004 and reached USD 460 million in 2005. In 2011, it grew rapidly to USD 2.46 billion.
Inquire this Report before buying @ http://www.chinamarketresearchreports.com/contacts/inquire-before-buy.php?name=114730 .
In the field of antitumor drugs in China, antimetabolic drug is one of the most common types among traditional antitumor chemotherapy drugs. Market size of pemetrexed in China has increased rapidly in recent years. The CAGR of its sales value exceeded 70% from 2006 to 2013.
Pemetrexed was approved to clinical use in China in 2004. It was approved to China in 2005 to treat malignant pleural mesothelioma. As a
The collection of ‘Life Sciences’ market research reports has a new addition of “Investigation Report on China Pemetrexed Market, 2009-2018”On chinamarketresearchreports.com . Pemetrexed, originally developed by Eli Lilly and Company, is a multitargeted antimetabolite antitumor drug. This product is with huge growth potential in the market.
Approved by FDA in February 2004, pemetrexed is to treat unresectable malignant pleural mesothelioma with cisplatin. It is the first drug approved by FDA to treat the disease. In August 2004 pemetrexed was approved as a secondline drug for local or metastatic nonsmall cell lung cancer.
So far pemetrexed (brand name "Alimta") has been approved to more than 60 countries worldwide. The product has been a best seller of Eli Lilly and Company since it was launched, and its sales value keeps increasing year after year. The CAGR of sales value of pemetrexed was 50.6% from 2004 to 2011. The sales value was only USD 140 million in 2004 and reached USD 460 million in 2005. In 2011, it grew rapidly to USD 2.46 billion.
Inquire this Report before buying @ http://www.chinamarketresearchreports.com/contacts/inquire-before-buy.php?name=114730 .
In the field of antitumor drugs in China, antimetabolic drug is one of the most common types among traditional antitumor chemotherapy drugs. Market size of pemetrexed in China has increased rapidly in recent years. The CAGR of its sales value exceeded 70% from 2006 to 2013.
Pemetrexed was approved to clinical use in China in 2004. It was approved to China in 2005 to treat malignant pleural mesothelioma. As a